Our translational medicine program helps us ensure that patients derive the greatest possible benefit from our drug candidates. Information from molecular profiling of tumors, patient’s treatment history and baseline characteristics are used to help pre-select patients with the greatest likelihood of responding positively to each of our treatments.
We integrate these translational medicine systems into each of our clinical programs and refine them as new data and observations are recorded. The understandings derived from our translational medicine programs also helps us to monitor the pharmacological activity of our compounds in patients, to elucidate their mechanism of action, identify any resistance mechanisms that may emerge, and potentially find additional cancers where patients could benefit from the therapy.
